A preliminary study to determine the effect of an infusion of cryopreserved autologous lymphocytes on immunocompetence and viral load in HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 2, 1998, Pages 129-136

  Trickett, Annette E ^a,b   Kelly, Mark ^b   Cameron, Barbara A ^b   Lloyd, Andrew ^b   Ffrench, Rose A ^c   Dwyer, John M ^b,d  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Adoptive cellular immunotherapy; HIV; Leukapheresis

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; LEUKAPHERESIS; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

EID: 0032006341     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802010-00005     Document Type: Article

References (35)

1. Ho DD, Pomerantz RJ, Kaplan JC. Pathogenesis of infection with human immunodeficiency virus. N Engl J Med 1987;317:278-6.
2. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328: 327-35.
3. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993;57:183-289.
4. Evans LA, Thomson-Honnebier G, Steimer K, et al. Antibody-dependent cellular cytotoxicity is directed against both gp120 and gp41 envelope proteins of HIV. AIDS 1989;3:273-89.
5. Robert-Guroff M, Brown M, Gallo RC. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985;316:72-4.
6. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328: 345-8.
7. Plata F, Autran B, Predoza Martins L, et al. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature 1987;328:348-51.
8. Walker CM, Moody DJ, Stiles DP, Levy JA. CD8+ Lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-6.
9. Hoffenbach A, Langlade-Demoyen P, Dadaglio G, et al. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 1989;142:452-62.
10. Baier M, Werner A, Bannert N, Metzner K, Kurth R. HIV suppression by interleukin-16. Nature 1995;378:563.
11. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1α, MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-15.
12. Trickett AE, Dwyer J, Tedla N, Lam-Po-Tang R. Safety and feasibility of harvesting cells for adoptive immunotherapy from patients with asymptomatic HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:523-4.
13. Rowley SD, Bensinger WI, Gooley TA, Buckner CD. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994;83:2731-6.
14. Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996;10:167-73.
15. Clerici M, Lucey DR, Zajac RA, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp120 in HIV-seropositive individuals. J Immunol 1991;146:2214-9.
16. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
17. Dwyer JM, Wood CC, McNamara J, Kinder B. Transplantation of thymic tissue into patients with AIDS. Arch Intern Med 1987;147: 513-7.
18. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of HIV infection with Saquinavir, Zidovudine, and Zalcitabine. N Engl J Med 1996;334:1011-7.
19. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in the CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997;3:533-40.
20. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
21. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996;124:1019-30.
22. Westermann J, Pabst R. Lymphocytes subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today 1990; 11:406-10.
23. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
24. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med 1996;2:216-23.
25. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-80.
26. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med 1996;2:625-9.
27. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
28. Torpey D, Huang XL, Armstrong J, et al. Effects of adoptive immunotherapy with Autologous CD8+ T lymphocytes on immunologic parameters: lymphocyte subsets and cytotoxic activity. Clin Immunol Immunopathol 1993;68:263-72.
29. Ho M, Armstrong J, McMahon D, et al. A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. Blood 1993;81:2093-101.
30. Klimas N, Patarca R, Walling J, et al. Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion. AIDS 1994;8:1073-81.
31. Lieberman J, Fabry JA, Skolnik PR, et al. Immunotherapy with autologous HIV-specific CTL [abstract PB0311]. X International Conference on AIDS, Yokohama, Japan, 1994.
32. Moskophidis D, Lechner F, Pircher H, Zinkemagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-61.
33. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995;13:545-86.
34. Sadat-Sowti B, Debré P, Idziorek T, et al. A lectin-binding soluble factor released by CD8+CD57+ lymphocytes from AIDS patients inhibits T cell cytotoxicity. Eur J Immunol 1991;21:737-41.
35. Phillips R, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:453-9.